Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sets New 1-Year High – Still a Buy?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) hit a new 52-week high during trading on Friday . The company traded as high as $13.09 and last traded at $13.05, with a volume of 54728 shares traded. The stock had previously closed at $12.91.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BAYRY. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Finally, Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Three equities research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. Based on data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 1.6%

The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The business has a fifty day simple moving average of $10.46 and a two-hundred day simple moving average of $8.88.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.